There has been much buzz lately about the side effects of Apricus Bio’s (APRI) topically applied erectile dysfunction treatment, Vitaros. Vitaros is an alprostadil-based cream and stands as a ...

SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI), announced today that Health Canada has granted marketing approval for Vitaros ® as a first-line therapy for ...

The pre-clinical and clinical data submitted earlier by Apricus was satisfactory for the approval according to Swissmedic. However, according to Swissmedic the data related to the targeted shelf life ...

Apricus Biosciences has received European approval to market alprostadil 0.3% topical cream (Vitaros) for the treatment of erectile dysfunction (ED), the company announced today. Vitaros is a ...

(www.apricusbio.com), today provided a corporate update. "Since the beginning of this year, we have continued to focus our efforts on creating long-term value through our lead product Vitaros® and our ...

(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...

SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it ...